Bayer: FDA Grants Priority Review To Lynkuet For New Indication

LEVERKUSEN (dpa-AFX) - Bayer (BYR.L, BAY.MI, BAYN.DE) announced the FDA has accepted the supplemental New Drug Application and granted Priority Review designation for Lynkuet under investigation for the treatment of moderate to severe vasomotor symptoms in women receiving endocrine therapy for trea…